Matinas BioPharma Announces Two Abstracts Accepted for Presentation on Preclinical Data of Lead Anti-Infective Product Candidates MAT2203 and MAT2501 at ICAAC/ICC 2015

Data demonstrating rapid tissue penetration in animal studies of oral encochleated Amphotericin B in systemic candidiasis to be presented on Sept. 18

Results of oral encochleated Amikacin in mycobacterium avium in vivo (lung biofilm) and in vitro (biofilm) models to be presented on Sept. 19

BEDMINSTER, N.J., July 14, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company, today announced that it will be presenting preclinical data on its two lead anti-infective product candidates, MAT2203 and MAT2501, at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy's International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) scientific meeting Sept. 17 - 21 in San Diego.

Matinas BioPharma will present preclinical data on MAT2203, the Company's novel lipid-crystal nano-particle delivered formulation of Amphotericin B, from an abstract entitled, "Oral Dosing of Encochleated Amphotericin B (CAmB): Rapid Drug Targeting to Infected Tissues in Mice with Systemic Candidiasis," on Friday, Sept. 18, noon - 2 p.m. in a poster session focused on Pharmacokinetics/Pharmacodynamics of New Drugs in Development. MAT2203, an oral broad spectrum fungicidal agent, is expected to enter Phase 2a clinical studies for the treatment of mucocutaneous fungal infections in collaboration with the National Institutes of Health/National Institute of Allergy and Infectious Disease (NIH/NIAID) this year.

Additionally, preclinical data on Matinas BioPharma's early-stage development program to treat gram-negative bacterial infections, MAT2501, will also be presented from a study entitled, "Oral Encochleated Amikacin Demonstrates Activity In Vivo and In Vitro in Biofilm Models of Mycobacterium avium," on Saturday, Sept. 19, 11 a.m. - 1 p.m., in a poster session on pneumonia. MAT2501 is a gram-negative aminoglycoside antibiotic delivered in the Company's proprietary lipid-crystal nano-particle cochleate formulation. Matinas BioPharma anticipates filing an investigational new drug (IND) application with the U.S. Food and Drug Administration for MAT2501 this year.

About Matinas BioPharma

Matinas BioPharma is a clinical-stage biopharmaceutical company with a principal focus on identifying and developing novel and targeted pharmaceutical products for the treatment of various infectious diseases, with additional programs developing therapies to treat cardiovascular and metabolic conditions. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas BioPharma is focused on creating highly differentiated, safe and efficacious therapies utilizing its expertise in drug formulation and development in order to address significant unmet medical needs. The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's strategic focus and the future development of its product candidates and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

CONTACT: Investor Contact
         Jenene Thomas
         Jenene Thomas Communications, LLC
         Phone: +1 (908) 938-1475
         Email: jthomas@matinasbiopharma.com

         Media Contact:
         David Connolly
         LaVoieHealthScience
         Phone: +1 (617) 374-8800
         Email: dconnolly@lavoiehealthscience.com

Released July 14, 2015